US009408872B2

(12) **United States Patent**
Borody

(10) **Patent No.: US 9,408,872 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **PROBIOTIC RECOLONISATION THERAPY**

(71) Applicant: **Crestovo LLC**, Greenwich, CT (US)

(72) Inventor: **Thomas Julius Borody**, Five Dock (AU)

(73) Assignee: **Crestovo LLC**, Greenwich, CT (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/793,642**

(22) Filed: **Jul. 7, 2015**

(65) **Prior Publication Data**

US 2015/0306156 A1 Oct. 29, 2015

Related U.S. Application Data

(60) Continuation of application No. 14/710,481, filed on May 12, 2015, and a continuation of application No. 14/710,487, filed on May 12, 2015, said application No. 14/710,481 is a continuation of application No.

(Continued)

(30) **Foreign Application Priority Data**

Jul. 25, 2000 (AU) PQ8997

(51) **Int. Cl.**

A61K 45/00	(2006.01)
A01N 63/00	(2006.01)
A61M 36/14	(2006.01)
A61K 9/16	(2006.01)
A61K 9/50	(2006.01)
A61K 35/24	(2015.01)
A61K 35/74	(2015.01)
A61K 38/48	(2006.01)
A23L 1/30	(2006.01)
A61K 35/741	(2015.01)
A61K 35/742	(2015.01)
A61K 35/744	(2015.01)
A61K 35/747	(2015.01)
A61K 36/062	(2006.01)
A61K 45/06	(2006.01)
A61K 38/14	(2006.01)
A61K 31/341	(2006.01)
A61K 31/41	(2006.01)
A61K 31/495	(2006.01)
A61K 31/7034	(2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ***A61K 35/24*** (2013.01); ***A23L 1/3014*** (2013.01); ***A23L 2/52*** (2013.01); ***A61K 31/341*** (2013.01); ***A61K 31/41*** (2013.01); ***A61K 31/495*** (2013.01); ***A61K 31/7034*** (2013.01); ***A61K 35/38*** (2013.01); ***A61K 35/74*** (2013.01); ***A61K 35/741*** (2013.01); ***A61K 35/742*** (2013.01); ***A61K 35/744*** (2013.01); ***A61K 35/745*** (2013.01); ***A61K 35/747*** (2013.01); ***A61K 36/062*** (2013.01); ***A61K 38/14*** (2013.01); ***A61K 38/4893*** (2013.01); ***A61K 45/06*** (2013.01); *A23V 2002/00* (2013.01); *A61K 9/5078* (2013.01); *A61K 31/43* (2013.01); *A61K 31/545* (2013.01); *A61K 31/7048* (2013.01); *A61K 35/76* (2013.01); *A61K 38/00* (2013.01); *A61K 39/00* (2013.01); *A61K 39/39* (2013.01); *A61K 51/1217* (2013.01); *A61K 2035/115* (2013.01); *C12N 2795/00032* (2013.01)

(58) **Field of Classification Search**

CPC . A61K 35/74; A61K 35/742; A61K 51/1217; A61K 9/0578

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,192,116 A * 6/1965 Mose A61K 35/74 424/93.41
3,320,130 A 5/1967 Henry

(Continued)

FOREIGN PATENT DOCUMENTS

AU 5 329 879 A 7/1980
AU 3 758 085 A 9/1985

(Continued)

OTHER PUBLICATIONS

Kobashi (Nov. 1980) Metabolism of Sennosides by Human Intestinal Bacteria, J Medicinal Plant Res., vol. 40, pp. 225-236.

(Continued)

Primary Examiner — Gary Nickol
Assistant Examiner — Lakia Tongue
(74) *Attorney, Agent, or Firm* — David R. Marsh; Arnold & Porter LLP

(57) **ABSTRACT**

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of *Bacteroides* , *Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli*, anaerobic cocci, Ruminococcus, *E. coli*, Gemmiger, Desulfomonas, *Peptostreptococcus*, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic *Escherichia coli*, at least one strain of viable non-pathogenic or attenuated pathogenic *Bacteroides* and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

30 Claims, No Drawings